

From: Alan Eisenman <[REDACTED]>
Sent: Thursday, September 10, 2015 6:21 AM
To: Geno Zawrotny <[REDACTED]>
Subject: Re: Theranos

Geno,

I need accurate information. Please let me know the total dollar amount of Theranos your firm has crossed since inception. What are the dollar amounts of the larger trades? What are the gross and net prices of the most recent trades? What net price can I expect for my stock if I want to sell \$100,000, \$1,000,000, or \$10,000,000. Is the market liquid enough to absorb \$10,000,000 without lowering my price?

Thanks,
 Alan

On Tue, Sep 8, 2015 at 7:13 PM, Geno Zawrotny <[REDACTED]> wrote:
 Hi Alan,

Sorry, I just returned from a week long vacation and I actually was unplugged for once. We can discuss when you get back from your vacation if you still have questions. No rush as we have several large blocks to fill in the next few months before we get to your price level. Have a nice vacation!

On Friday, September 4, 2015, Alan Eisenman <[REDACTED]> wrote:
 Hi Bryson,

This conflicts with my conversation with Geno. I thought he said that your firm had done several transactions in Theranos stock, and current transactions were selling in the 17-19 dollar price range, before commission. He also said that the company had exercised it's first right of refusal on some of the transactions and purchased stock for as much as \$17.40. I need current and accurate information, so I can set my prices and quantities. Can you confirm with Geno and respond today?

Thank you,
 Alan Eisenman

On Thu, Sep 3, 2015 at 7:17 PM, Bryson Tombridge <[REDACTED]> wrote:
 Hi Alan,


Yes, we received your documentation. Thank you for sending it in to us; we have everything that we need for now.

We completed a \$9.2MM transaction earlier this year at a notice price of \$14.75. This is our only transaction in Theranos.

In terms of the market, we have a large block of sellers at \$19.00 per share. Our typical fee is 5%, which is negotiable in some cases for large quantities.

I hope this information is helpful.

Best regards,
 Bryson



On Thu, Sep 3, 2015 at 12:52 PM, Alan Eisenman <[REDACTED]> wrote:

Bryson,

I wanted to make sure you received all documentation to list my Theranos for sale. Could you update me on the current market...where stock has been trading, both gross sales price and net of commissions, and also how much stock is in front of me and at what price. Could you also give me a sense of the depth of the market in case I want to sell a large quantity. Finally, what commission break can you offer if I sell a larger quantity?

Thanks,
Alan Eisenman

Bryson Tombridge | Associate, Private Securities

SharesPost
221. Pine Street, 6th Floor
San Francisco, CA 94104

[REDACTED] office

Securities offered through SharesPost Financial Corporation, Member FINRA/SIPC
Member Broker-Dealer on NASDAQ Private Market

[Introducing the SharesPost 100 Fund](#)

btombridge@sharespost.com | sharespost.com

Past performance is not necessarily indicative of future results. This message is intended only for the personal and confidential use of the designated recipient(s). If you are not the intended recipient of this message you are hereby notified that any review, dissemination, distribution or copying of this message is strictly prohibited.

DISCLAIMER:

THE SHARESPOST 100 FUND'S PROSPECTUS CONTAINS INFORMATION REGARDING THE FUND'S INVESTMENT OBJECTIVES, RISKS, AND CHARGES AND EXPENSES. YOU SHOULD READ THE PROSPECTUS CAREFULLY BEFORE INVESTING. INVESTORS MAY RELY ONLY ON THE INFORMATION CONTAINED IN THE FUND'S PROSPECTUS CONCERNING THE OFFERING OF THE FUND'S SHARES. NO PERSON OR THIRD PARTY PUBLICATION IS AUTHORIZED TO PROVIDE ANY INFORMATION NOT INCLUDED IN THE PROSPECTUS AND NO SUCH INFORMATION SHOULD BE RELIED UPON.

Best,

Geno Zawrotny | Vice President, Private Securities Group
SharesPost Financial Corporation, Member FINRA / SIPC

[REDACTED] phone

[REDACTED] | sharespost.com

Past performance is not necessarily indicative of future results. This message is intended only for the personal and confidential use of the designated recipient(s). If you are not the intended recipient of this message you are hereby notified that any review, dissemination, distribution or copying of this message is strictly prohibited.

CONFIDENTIAL TREATMENT
REQUESTED BY SHARESPOST

SPST_SF_4030_0036279

USAO-SEC-0004978